Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: A randomized clinical trial

Psychotherapy and Psychosomatics

Volumn 85, Issue 6, 2016, Pages 346-356

  Nordahl, Hans M ^a   Vogel, Patrick A ^a   Morken, Gunnar ^a   Stiles, Tore C ^a   Sandvik, Pål ^b   Wells, Adrian ^c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cognitive therapy; Metacognitive therapy; Paroxetine; Randomized controlled trial; Social phobia

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; ASTHENIA; AVOIDANT PERSONALITY DISORDER; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LIEBOWITZ SOCIAL ANXIETY SCALE; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREMOR; XEROSTOMIA; ADOLESCENT; AGED; COMPLICATION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PERSONALITY DISORDERS; PHOBIA, SOCIAL; PROCEDURES; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COGNITIVE THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PERSONALITY DISORDERS; PHOBIA, SOCIAL; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 84991757079     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000447013     Document Type: Article

References (45)

1. Kessler RC, Stein MB, Berglund P: Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998; 155: 613-619.
2. Schneier FR: Social anxiety disorder is common, underdiagnosed, impairing and treatable. BMJ 2003; 327: 515-516.
3. Blanco C, Heimberg RG, Schneier, FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67: 286-295.
4. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalised social phobia: a randomized controlled trial. JAMA 1998; 280: 708-713.
5. Davidson J: Pharmacotherapy of social phobia. Acta Psych Scand Suppl 2003; 417: 65-71.
6. Mayo-Wilson E, Dias S, Mavranezouli I, Kayleigh K, Clark DM, Ades AE, Pilling S: Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-Analysis. Lancet Psychiatry 2014; 1: 368-376.
7. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, Liebowitz MR: Pharmacological treatment of social anxiety disorder: a meta-Analysis. Depress Anxiety 2003; 18: 29-40.
8. Acaturk C, Cuijpers P, van Straten A, de Graaf R: Psychological treatment of social anxiety disorder: a meta-Analysis. Psychol Med 2009; 39: 241-254.
9. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioural therapy and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61: 1005-1013.
10. Clark DM, Wells A: A cognitive model of social phobia in Liebowitz MR, Hope DA, Schneier FR (eds) Social phobia: Diagnosis, Assessment, and Treatment. New York, Guilford Press, pp 41-68.
11. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalised social phobia: a randomised placebo-controlled trial. J Con Clin Psychol 2003; 71: 1058-1067.
12. Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: Cognitive therapy versus exposure and applied relaxation in social phobia: a randomised controlled trial. J Con Clin Psychol 2006; 74: 568-578.
13. Wells A, Papageorgiou C: Brief cognitive therapy for social phobia: a case series. Behav Res Ther 2001; 39: 713-720.
14. Faloon IR, Lloyd GG, Harpin RE: The treatment of social phobia: real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis 1981; 169: 180-184.
15. Clark DB, Agras WS: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991; 148: 598-605.
16. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179: 23-30.
17. Hoffman SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006, 63: 298-304.
18. Guastella AJ, Rickardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63: 298-304.
19. Wells A: Cognitive Therapy of Anxiety Disorders: A Practice Manual and Conceptual Guide. Chichester, Wiley, 1997.
20. Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D: Efficacy of treatments for anxiety disorders: a meta-Analysis. Int Clin Psychopharmacol 2015; 30: 183-192.
21. Rodebaugh TL, Holaway RM, Heimberg RG: The treatment of social anxiety disorder. Clin Psychol Rev 2004; 24: 883-908.
22. Finniss, DG, Kaptchuk, TJ, Miller F, Benedetti F: Biological, clinical and ethical advances of placebo effects. Lancet 2010; 375: 686-695.
23. Di Nardo PA, Brown TA, Barlow DH: Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV). Albany, Graywind, 1994.
24. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS: User s Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, American Psychiatric Press, 1997.
25. Stein, DJ, Ipser JC, van Balkom JA: Pharmacotherapy for Social Anxiety Disorder. Cochrane Collaboration. Hoboken, Wiley, 2009.
26. Watson D, Friend, R: Measurement of socialevaluative anxiety. J Con Clin Psychol 1969; 33: 448-457.
27. Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Con Clin Psychol 1991; 59: 12-19.
28. Liebowitz MR: Social phobia. Mod Probl Pharm Psychiatry 1987; 22: 141-173.
29. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. J Con Clin Psychol 1988; 56: 893-897.
30. Horowitz LM, Rosenberg SE, Baer BA, Ureno G, Villasenor VS: Inventory of interpersonal problems: psychometric properties and clinical applications. J Con Clin Psychol 1988; 56: 885-892.
31. Heck RH, Thomas SL, Tabata LN: Multilevel and Longitudinal Modeling with IBM SPSS, ed 2. New York, Routledge, 2014.
32. Cohen J: Statistical Power Analysis for the Behavioural Sciences, ed 2. New Jersey, Lawrence Erlbaum, 1988.
33. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, Vold JE: Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003; 182: 312-318.
34. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993; 162: 776-787.
35. Barlow DH, Gorman JM, Shear, MK, Woods SW: Cognitive-behavioural therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283: 2529-2536.
36. Fava, GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72-81.
37. Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015;84: 63-71.
38. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behaviour therapy. Psychother Psychosom 2014; 83: 247-248.
39. Basoglu M, Marks IM, Kilic C, Brewin CR, Swinson RP: Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br J Psychiatry 1994; 164: 652-659.
40. Ginzburg DM, Bohn C, Hofling V, Weck F, Clark DM, Stangier U: Treatment specific competence predicts outcome in cognitive therapy for social anxiety disorder. Behav Res Ther 2012; 50: 747-752.
41. Offidani E, Guidi J, Tomba E, Fava GA Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and metaanalysis. Psychother Psychosom 2013; 355-362.
42. Scott J, Young, AH: Psychotherapies should be assessed for both benefit and harm. Br J Psychiatry 2016; 208: 208-209.
43. Parry G, Crawford MJ, Duggan C: Iatrogenic harm from psychological therapies-Time to move on. Br J Psychiatry 2016; 208: 210-212.
44. Ingul JM, Aune T, Nordahl HM: A randomised controlled trial of Individual cognitive therapy, group cognitive therapy and attentional placebo for adolescent social phobia. Psychother Psychosom 2014; 83: 54-61.
45. Fava GA, Grandi S, Rafanelli C, Ruini C, Conti S, Belluardo P: Long-Term outcome of social phobia treated by exposure. Psychol Med 2001; 31: 899-905.